Adjuvant Endocrine Therapy Trials in Premenopausal Patients

The International Breast Cancer Conference has demonstrated that adjuvant ovarian ablation significantly reduces mortality in premenopausal women, and tamoxifen reduces mortality in both pre- and postmenopausal women with ER-positive tumors. Current clinical trials are addressing a number of important issues related to these two key interventions, including the impact of combining these therapies with chemotherapy. New trials are also combining aromatase inhibitors and ovarian suppression in premenopausal women, particularly in light of the recent ATAC trial data demonstrating an advantage to anastrozole in postmenopausal women.

**SOURCE:** NC2 Physician Data Query, February 2003.

**KEY QUESTIONS IN THE MANAGEMENT OF PREMENOPAUSAL PATIENTS WITH ER/PR-POSITIVE TUMORS**

- Importance of amenorrhea as a determinant of therapy
- Optimal duration of ovarian ablation if an LHRH analogue is used
- Value of ovarian ablation after chemotherapy, particularly for women who remain premenopausal after adjuvant chemotherapy
- Utility of combined hormone therapy such as ovarian ablation with tamoxifen, or aromatase inhibitors
- Long-term side effects of ovarian suppression

**SOURCE:** NC2 Physician Data Query, February 2003.

**INT-0101 TRIAL RESULTS: 7.4 YEARS FOLLOW-UP**

<table>
<thead>
<tr>
<th>DFS</th>
<th>Survival</th>
<th>DFS &lt; 40 yrs old</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAF</td>
<td>58%</td>
<td>77%</td>
</tr>
<tr>
<td>CAFZ</td>
<td>64%</td>
<td>78%</td>
</tr>
<tr>
<td>CAFZT</td>
<td>73%</td>
<td>80%</td>
</tr>
</tbody>
</table>

**DERIVED FROM:** NE Davidson, Presentation, San Antonio Breast Cancer Symposium, 2001.

**PLANNED OR ONGOING TRIALS OF ADJUVANT ENDOCRINE THERAPY IN PREMENOPAUSAL PATIENTS**

**SELECT PUBLICATIONS**


**DERIVED FROM:** ASCO Technology Assessment: Aromatase inhibitors as adjuvant therapy for women with hormone receptor positive breast cancer.